Could one pill a day control this esophagus disease as well as two?

NCT ID NCT06596252

Recruiting now Disease control Sponsor: Dr. Falk Pharma GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests if taking a budesonide tablet once daily works as well as taking it twice daily for adults with eosinophilic esophagitis, a condition where immune cells damage the esophagus. About 308 adults with active disease will receive one of the two dosing schedules for 6 weeks. The goal is to see if the simpler once-daily dose can achieve similar remission rates with fewer daily doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC ESOPHAGITIS

Contacts and locations

Locations

Department of Gastroenterology, Hospital General de Tomelloso
RECRUITING

Tomelloso, 13700, Spain
Dr. Falk Investigational Site
RECRUITING

Scottsdale, Arizona, 85259, United States
Dr. Falk Investigational Site
RECRUITING

Little Rock, Arkansas, 72205, United States
Dr. Falk Investigational Site
RECRUITING

La Jolla, California, 92037, United States
Dr. Falk Investigational Site
WITHDRAWN

Lomita, California, 90717, United States
Dr. Falk Investigational Site
RECRUITING

San Diego, California, 92193, United States
Dr. Falk Investigational Site
RECRUITING

Doral, Florida, 83706, United States
Dr. Falk Investigational Site
RECRUITING

New Port Richey, Florida, 34653, United States
Dr. Falk Investigational Site
RECRUITING

Boise, Idaho, 83706, United States
Dr. Falk Investigational Site
WITHDRAWN

Houma, Louisiana, 70363, United States
Dr. Falk Investigational Site
WITHDRAWN

Marrero, Louisiana, 70072, United States
Dr. Falk Investigational Site
RECRUITING

Boston, Massachusetts, 02111, United States
Dr. Falk Investigational Site
RECRUITING

Plymouth, Michigan, 55446, United States
Dr. Falk Investigational Site
RECRUITING

Wyoming, Michigan, 49519, United States
Dr. Falk Investigational Site
RECRUITING

Rochester, Minnesota, 55905, United States
Dr. Falk Investigational Site
RECRUITING

Freehold, New Jersey, 07728, United States
Dr. Falk Investigational Site
WITHDRAWN

Jackson, New Jersey, 08527, United States
Dr. Falk Investigational Site
RECRUITING

New York, New York, 10075, United States
Dr. Falk Investigational Site
RECRUITING

Chapel Hill, North Carolina, 27599-7080, United States
Dr. Falk Investigational Site
RECRUITING

Cleveland, Ohio, 44195, United States
Dr. Falk Investigational Site
RECRUITING

Mentor, Ohio, 44060, United States
Dr. Falk Investigational Site
RECRUITING

Harlingen, Texas, 78550, United States
Dr. Falk Investigational Site
RECRUITING

Salt Lake City, Utah, 85259, United States
Dr. Falk Investigational Site
NOT_YET_RECRUITING

Charlottesville, Virginia, 22903, United States
Dr. Falk Investigational Site
RECRUITING

Lynchburg, Virginia, 24502, United States
Wyoming
RECRUITING

Ann Arbor, Michigan, 48109, United States
Wyoming
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.